Key result
p38 MAPK inhibition plus antibacterial therapy reduces intestinal dysfunction severity in rats with experimental peritonitis.
Why the study?
Identifying new strategies to restore intestinal wall integrity and prevent abdominal sepsis remains a pressing medical issue.
Does a p38 MAPK inhibitor reduce the severity of intestinal dysfunction in a rat model of suppurative peritonitis under antibacterial therapy?
Does a p38 MAPK inhibitor reduce the severity of intestinal dysfunction in a rat model of suppurative peritonitis under antibacterial therapy?
p-value: p=0.005
In a rat model of suppurative peritonitis, the addition of a p38 MAPK inhibitor to antibacterial therapy significantly attenuated destructive changes in the intestinal wall.
Hypothesis-generating in rat peritonitis; leaves open translation to human intestinal dysfunction.
No takes yet. Share an insight, caveat, or question.
Чепурных et al. (2025) studied Experimental suppurative peritonitis and intestinal dysfunction. p38 MAPK inhibitor + antibacterial therapy vs. Saline + antibacterial therapy was evaluated on Severity of intestinal dysfunction and destructive changes in the intestinal wall (p=0.005). Administration of a p38 MAPK inhibitor alongside antibacterial therapy significantly reduced the severity of intestinal dysfunction in rats with experimental peritonitis (p=0.005 on days 3 and 7).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: